As healthcare organizations turn their attention toward 2026 planning, many finance and revenue leaders are finalizing budgets, forecasts, and growth priorities. Yet one critical step is often overlooked at year-end:
Closing out unresolved financial exposure from the prior year.
For hospitals, outpatient facilities, and infusion centers administering high-cost, provider-billed drugs, year-end housekeeping is more than an administrative exercise. It’s a practical way to protect margin, reduce uncertainty, and enter the new year with clarity.
Why Year-End Housekeeping Matters
Medical-benefit drug spend continues to rise while reimbursement pressure remains persistent. In this environment, even a small set of unreviewed claims can quietly create financial blind spots.
These gaps often occur when:
- Claims are excluded due to uncertainty around eligibility
- Manufacturer submission timelines are misunderstood
- Year-end close happens before all rebate-eligible activity is reviewed
Many organizations assume that once the calendar year ends, opportunities tied to prior claims are no longer accessible. In reality, that isn’t always the case.
A Practical Year-End Checklist
Before closing the books on 2025, healthcare finance teams may want to consider:
- Were there medical-benefit drug claims in 2025 that were never reviewed for rebate eligibility?
- Were certain claims set aside due to questions around 340B status, GPO participation, or site-of-care rules?
- Do you have clear visibility into manufacturer submission deadlines tied to prior-year claims?
- Are you entering 2026 with confidence that 2025 exposure has been fully assessed?
Addressing these questions now can prevent missed opportunities and reduce uncertainty early in the new year.
Understanding Lookback Windows
Rebate submission timelines vary by manufacturer and program. However, many healthcare organizations are surprised to learn that some rebate programs allow limited retroactive review windows after year-end.
While rules differ:
- Medical-benefit rebate programs often allow lookbacks of up to 90 days
- Pharmacy-related rebate programs may allow longer windows in certain cases
This makes early Q1 a critical planning period, not just a reset. Organizations that identify open questions before year-end are better positioned to act within allowable windows rather than discovering issues after deadlines have passed.
Preparing for a Cleaner 2026
Year-end housekeeping isn’t about chasing revenue after the fact. It’s about entering the new year with accurate baselines, stronger audit readiness, and fewer financial surprises.
Healthcare organizations that incorporate Strategic Rebate Management into their year-end review process are often better equipped to:
- Improve forecasting accuracy
- Support compliance and documentation efforts
- Navigate rising specialty drug costs with greater confidence
In a complex reimbursement environment, clarity is a competitive advantage.
Final Thought
Before finalizing your 2026 plans, it’s worth asking a simple question:
Is everything from 2025 truly closed?
A small amount of diligence now can make a meaningful difference in the year ahead.
Disclaimer: This article is provided by VativoRx for informational and educational purposes only and does not constitute legal, regulatory, or financial advice. Rebate eligibility, submission timelines, and lookback periods vary by manufacturer program and are subject to applicable contracts and laws. Organizations should consult their legal and compliance advisors regarding specific eligibility and submission requirements.
